🟢 Inovio Pharmaceuticals is trading 5.7% up in after-hours trading after upbeat outlook on INO-3107 FDA decision

Inovio Pharmaceuticals is trading at $1.39, up 5.66%, after management presented an upbeat outlook at the Cantor Fitzgerald Global Healthcare Conference on September 9, 2026.

• INO-3107 FDA decision remains scheduled for October 30, 2026; management also highlighted potential commercial preparations.
• Regular-session close was $1.32, down 7.04%.
• The after-hours gain contrasted with the regular-session decline and broader market weakness, suggesting a response to the company-specific regulatory update; risk-off trading likely limited the rebound.